TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that its board of directors will meet on April 24, 2025, to review and approve the company’s first-quarter results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance, potentially impacting its market positioning and stakeholder interests.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, focusing on the production and distribution of heparin products and other pharmaceutical services.
YTD Price Performance: 5.05%
Average Trading Volume: 3,652,923
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.42B
Learn more about 9989 stock on TipRanks’ Stock Analysis page.